news

NIIMBL announces funding for Covid projects

FactoryFuture • December 21, 2021 • 2 min read

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) yesterday announced its decision to award 32 coronavirus response projects to multiple organizations across the United States funded through…

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) yesterday announced its decision to award 32 coronavirus response projects to multiple organizations across the United States funded through the American Rescue Plan (ARP).   NIIMBL targeted and identified worthy projects that will help the nation prevent, prepare for, and respond to coronavirus public health threats. Six of the 32 chosen projects have been designated to establish research and development testbeds that will support collaborative research and innovation by the NIIMBL community at the NIIMBL headquarters in Newark, DE.   Kelvin Lee, the Director of NIIMBL announced the project funding, declaring “To move past the current pandemic and prevent and prepare for future public health threats, we must continue to create the technology, infrastructure, and skills that are needed. This diverse group of technology and workforce development projects addresses multiple public health response capabilities and strengthens the United States’ role as a global leader in biopharmaceutical manufacturing.”   The projects marked for ARP funding by NIIMBL have been chosen in order to accomplish the following:
  • Provide testbeds for process development, for next generation manufacturing approaches, and for drug product manufacturing approaches that provide access to industrially relevant equipment and facilities for pre-competitive manufacturing innovation
  • Support the development of significantly improved methods for vaccine production, quality, and distribution, including mRNA and other vaccine platforms
  • Demonstrate rapid scaling for production of coronavirus antigens and medical countermeasures for variants of concern
  • Train a diverse biopharmaceutical manufacturing workforce
  • Demonstrate the concept of mobile Good Manufacturing Practices capabilities to support mRNA vaccine and gene therapy production
Author

FactoryFuture

See all articles →

Related articles

Most Read